Oragenics, Inc.

203 articles about Oragenics, Inc.

• Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress

  9/23/2019

  Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces that an abstract from its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of AG013 in severe oral mucositis, will be presented as a poster at the upcoming European Society of Medical Oncology Congress (“ESMO”) on September 27 – October 1, 2019, in Barcelona, Spain,.

• Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

  9/6/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced that Alan Joslyn, president and CEO of Oragenics, Inc. will be a featured presenter at the 21st Annual Rodman and Renshaw Global Investment Conference on Tuesday September 10, 2019 at 3:25 PM Eastern Time

• Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium

  8/20/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in the Pharmacopeia”, which will be part of a session dedicated to novel antimicrobial developments to counter multidrug-resistant bacterial infections in military personnel.

• Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

  6/25/2019

  The presentation is scheduled on Wednesday, June 26, 2019, at the American Peptide Symposium in the Sierra Ballroom of the Monterey Conference Center in Monterey, Calif.

• Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action

  6/17/2019

  The study was published in the recent issue of Physical Chemistry Chemical Physics and results from our recent collaboration with researchers from Florida International University

• Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

  5/20/2019

  Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound

• Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract

  5/13/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lantibiotic compound OG253,

• Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019

  3/28/2019

  Oragenics, Inc. announced it will present and meet with investors at Spring Investor Summit on April 1, 2019 at 1:00 PM ET as part of Track 1 at The Essex House in New York City.

• Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics

  3/27/2019

  Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the initiation of a collaboration with Florida International University (FIU) to create computational models of the company’s lantibiotic compounds interacting with bacterial membranes and Lipid II, the target of Oragenics’ compounds with the ultimate goal of expanding the lantibiotic pipeline.

• Oragenics Announces Closing of $12.5 Million Underwritten Public Offering

  3/25/2019

  Oragenics, Inc. announced the closing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75 per share and accompanying warrants.

• Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering

  3/21/2019

  Oragenics, Inc. announced the pricing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75 per share and accompanying warrants.

• Organics Announces Proposed Underwritten Public Offering

  3/20/2019

  Oragenics, Inc. announced that it has commenced a proposed underwritten public offering of common stock of the Company, together with warrants to purchase shares of common stock.

• Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial

  3/15/2019

  Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces the enrollment of the 60th patient in its Phase 2 double blind, placebo controlled clinical trial of AG013.

• Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 - 19, 2019

  3/15/2019

  Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc.

• Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

  1/28/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer reviewed journal, Antimicrobial Agents and Chemotherapy.

• Oragenics Inc. to Present at NobleCon15 on January 28, 2019

  1/25/2019

  Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announced today that Alan Joslyn, Ph.D., president and CEO of Oragenics will be a featured presenter at NobleCon15 - Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at 10:30 AM Eastern Standard Time.

• Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives

  11/27/2018

  Lantibiotics are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacterial strains to attack competing bacteria.

• Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

  11/15/2018

  Oragenics, Inc. announced financial results for the quarter ended September 30, 2018.

• Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

  11/15/2018

  Oragenics, Inc. today announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute and patients residing in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA), into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM.

• Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

  10/17/2018

  Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM.